Overview

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
Phase:
N/A
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Alemtuzumab
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Mesna
Vidarabine